User login
Key clinical point: Vitamin D3 supplementation might improve headache characteristics and protect against inflammation in migraine.
Major finding: Analysis of covariance adjusted for baseline values and confounders showed that vitamin D3 supplemented group had significantly lower headache days, attacks frequency, duration and severity, and reduced analgesics consumption compared with the placebo group
(P less than 0.05). Patients receiving vitamin D3 had a significant reduction in inducible nitric oxide synthase
(P=0.001) and serum levels of interleukin-6 (P=0.055) compared with placebo.
Study details: Study of 80 patients with episodic migraine randomly assigned to a daily dose of vitamin D3 2,000 IU (50 μg) or placebo for 12 weeks.
Disclosures: The study was supported by Tehran University of Medical Sciences & health Services grant. The authors declared no conflict of interest.
Citation: Ghorbani Z et al. Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04220-8.
Key clinical point: Vitamin D3 supplementation might improve headache characteristics and protect against inflammation in migraine.
Major finding: Analysis of covariance adjusted for baseline values and confounders showed that vitamin D3 supplemented group had significantly lower headache days, attacks frequency, duration and severity, and reduced analgesics consumption compared with the placebo group
(P less than 0.05). Patients receiving vitamin D3 had a significant reduction in inducible nitric oxide synthase
(P=0.001) and serum levels of interleukin-6 (P=0.055) compared with placebo.
Study details: Study of 80 patients with episodic migraine randomly assigned to a daily dose of vitamin D3 2,000 IU (50 μg) or placebo for 12 weeks.
Disclosures: The study was supported by Tehran University of Medical Sciences & health Services grant. The authors declared no conflict of interest.
Citation: Ghorbani Z et al. Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04220-8.
Key clinical point: Vitamin D3 supplementation might improve headache characteristics and protect against inflammation in migraine.
Major finding: Analysis of covariance adjusted for baseline values and confounders showed that vitamin D3 supplemented group had significantly lower headache days, attacks frequency, duration and severity, and reduced analgesics consumption compared with the placebo group
(P less than 0.05). Patients receiving vitamin D3 had a significant reduction in inducible nitric oxide synthase
(P=0.001) and serum levels of interleukin-6 (P=0.055) compared with placebo.
Study details: Study of 80 patients with episodic migraine randomly assigned to a daily dose of vitamin D3 2,000 IU (50 μg) or placebo for 12 weeks.
Disclosures: The study was supported by Tehran University of Medical Sciences & health Services grant. The authors declared no conflict of interest.
Citation: Ghorbani Z et al. Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04220-8.